Biotech Stocks: The Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer

The bloodbath continued for biotech stocks Monday as the J.P. Morgan Healthcare Conference kicked off with massive deals for Pfizer (PFE) and Bayer (BAYRY).


Pfizer is teaming up with Beam Therapeutics (BEAM), Codex DNA (DNAY) and Acuitas Therapeutics. The partnerships are around base editing — a new form of gene editing — and messenger RNA. Meanwhile, Bayer said it would partner with Mammoth Biosciences to study gene-editing approaches to liver diseases.

Biotech stocks…

Read More